+关注
再战
暂无个人介绍
IP属地:浙江
37
关注
2
粉丝
0
主题
0
勋章
主贴
热门
再战
2021-07-26
的确,感觉像是在写童话故事[微笑]
抱歉,原内容已删除
再战
2021-03-02
这篇文章不错,转发给大家看看
抱歉,原内容已删除
再战
2021-02-11
这篇文章不错,转发给大家看看
抱歉,原内容已删除
再战
2021-02-05
这篇文章不错,转发给大家看看
抱歉,原内容已删除
再战
2019-12-18
$聚美优品(JMEI)$
请问各位大佬,聚美半年报有发过吗?都快年底了,谢谢!
再战
2019-09-04
$聚美优品(JMEI)$
什么时候能够出半年报,已经9月了
再战
2018-10-04
$奥驰亚(MO)$ 请问各位大咖,分红款何时能够到账啊?
再战
2018-08-07
集思广益,共同商讨应对之策
$聚美优品(JMEI)$ 当前聚美优品这样的一个股价表现,个人感觉有三点可能的原因:一、陈欧想要退市,之前私有化失败后,他准备用更便宜价格以回购方式进行退市,所以故意打压股价,一方面可以便宜价格回购股票,另一方面逼小股东退出,因为按照纽交所的退市规定,总股东数小于400人就将启动退市程序;二、投资者不看好公司发展前景,特别是现在街电的一审败诉,二审前景不明,投资者恐慌性抛售;三、聚美一直提供虚假报表,现在编不下去了,所以一方面一直不发布报表,另一方面干脆买光流通股退市算了。但不管是哪种情况,聚美对投资者不重视是肯定的,聚美官网上提供的联系电话和邮箱都是外包第三方公司的,电话打过去,一个接电话的男士永远都说聚美的事情由他同事在负责,同事很忙一直在出差,让我有事发邮件,很快会有答复,于是我信了,发了好几次邮件,但都似泥牛入海,音信全无!不信大家可以打电话发邮件试试。(网址:ir.jumei.com) 个人认为现在可以采取两种处理方式,一种是美国式的做法,也就是说,论坛里有没有熟悉美国法律的大牛牵个头,大家抱团集体起诉聚美,费用按持股份额共摊,聚美到现在为止未披露今年任何的报表信息,一定是有原因的,街电诉讼这么大的事件未见披露也不正常,论坛里的高人可以帮着找找诉讼理由;第二种就是中国式的做法,大家组群约个时间去聚美的办公地点,要求他们给股东一个说法,不给他们压力,他们根本就不理我们,对不对? 个人建议持股的兄弟姐妹现在不要再抛聚美股票了,三点理由:一、如果聚美是通过回购来实现退市,那么不能让他们以这么便宜的价格得手;二、如果投资者失去信心,但毕竟聚美还有那么多现金,还有宝宝树的股权,街电12口出问题但还有6口的,电视剧收视率也还高的,按照现在的市值计算已经低估,这个价位真是没必要再割肉了;三、如果聚美涉嫌欺诈,那把股票卖了,如何进行维权索赔呢? 抛砖引玉,欢迎大家集思广益,共同商
集思广益,共同商讨应对之策
再战
2017-07-11
感觉这里像赌场
$特斯拉(TSLA)$ 老虎的论坛里到处都是谈论期权的帖子,好像所有人都在期权里赚了大钱!期权就像赌博,长期来看“十赌九输”,从没听说过哪个投资大师是靠期权博取了超额利润!这个帖子发出肯定会受到一大帮期权“高手们”狠喷,即使这样我还是要提醒一句“远离期权、远离赌场”,如果你看好一支股票,那就买正股吧!有多少钱买多少股,不要加杠杆,祝虎友们投资发大财!
感觉这里像赌场
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3456483327764574","uuid":"3456483327764574","gmtCreate":1493389307415,"gmtModify":1706620600346,"name":"再战","pinyin":"zzzaizhan","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":37,"tweetSize":9,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":45,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.09%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.19","exceedPercentage":"60.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"浙江","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":800346229,"gmtCreate":1627281894961,"gmtModify":1627281894961,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"的确,感觉像是在写童话故事[微笑] ","listText":"的确,感觉像是在写童话故事[微笑] ","text":"的确,感觉像是在写童话故事[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800346229","repostId":"1199944196","repostType":4,"isVote":1,"tweetType":1,"viewCount":1549,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":362423387,"gmtCreate":1614659610749,"gmtModify":1703479490834,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"这篇文章不错,转发给大家看看","listText":"这篇文章不错,转发给大家看看","text":"这篇文章不错,转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/362423387","repostId":"2114034843","repostType":4,"isVote":1,"tweetType":1,"viewCount":1755,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":388981548,"gmtCreate":1613010595284,"gmtModify":1703768337392,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"这篇文章不错,转发给大家看看","listText":"这篇文章不错,转发给大家看看","text":"这篇文章不错,转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/388981548","repostId":"2103135838","repostType":2,"isVote":1,"tweetType":1,"viewCount":1106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":317715782,"gmtCreate":1612485478546,"gmtModify":1703762507183,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"这篇文章不错,转发给大家看看","listText":"这篇文章不错,转发给大家看看","text":"这篇文章不错,转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/317715782","repostId":"2108793032","repostType":2,"isVote":1,"tweetType":1,"viewCount":1686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":919866147,"gmtCreate":1576623790989,"gmtModify":1704272095795,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JMEI\">$聚美优品(JMEI)$</a>请问各位大佬,聚美半年报有发过吗?都快年底了,谢谢!","listText":"<a href=\"https://laohu8.com/S/JMEI\">$聚美优品(JMEI)$</a>请问各位大佬,聚美半年报有发过吗?都快年底了,谢谢!","text":"$聚美优品(JMEI)$请问各位大佬,聚美半年报有发过吗?都快年底了,谢谢!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/919866147","isVote":1,"tweetType":1,"viewCount":2569,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":997236574,"gmtCreate":1567554851998,"gmtModify":1704716321964,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JMEI\">$聚美优品(JMEI)$</a>什么时候能够出半年报,已经9月了","listText":"<a href=\"https://laohu8.com/S/JMEI\">$聚美优品(JMEI)$</a>什么时候能够出半年报,已经9月了","text":"$聚美优品(JMEI)$什么时候能够出半年报,已经9月了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/997236574","isVote":1,"tweetType":1,"viewCount":3061,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3496719751318586","authorId":"3496719751318586","name":"Alexliu169","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3496719751318586","idStr":"3496719751318586"},"content":"说是9月9","text":"说是9月9","html":"说是9月9"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":288994,"gmtCreate":1538664190964,"gmtModify":1704776153517,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"$奥驰亚(MO)$ 请问各位大咖,分红款何时能够到账啊?","listText":"$奥驰亚(MO)$ 请问各位大咖,分红款何时能够到账啊?","text":"$奥驰亚(MO)$ 请问各位大咖,分红款何时能够到账啊?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/288994","isVote":1,"tweetType":1,"viewCount":3253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":236524,"gmtCreate":1533616203588,"gmtModify":1704769514351,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"title":"集思广益,共同商讨应对之策","htmlText":"$聚美优品(JMEI)$ 当前聚美优品这样的一个股价表现,个人感觉有三点可能的原因:一、陈欧想要退市,之前私有化失败后,他准备用更便宜价格以回购方式进行退市,所以故意打压股价,一方面可以便宜价格回购股票,另一方面逼小股东退出,因为按照纽交所的退市规定,总股东数小于400人就将启动退市程序;二、投资者不看好公司发展前景,特别是现在街电的一审败诉,二审前景不明,投资者恐慌性抛售;三、聚美一直提供虚假报表,现在编不下去了,所以一方面一直不发布报表,另一方面干脆买光流通股退市算了。但不管是哪种情况,聚美对投资者不重视是肯定的,聚美官网上提供的联系电话和邮箱都是外包第三方公司的,电话打过去,一个接电话的男士永远都说聚美的事情由他同事在负责,同事很忙一直在出差,让我有事发邮件,很快会有答复,于是我信了,发了好几次邮件,但都似泥牛入海,音信全无!不信大家可以打电话发邮件试试。(网址:ir.jumei.com) 个人认为现在可以采取两种处理方式,一种是美国式的做法,也就是说,论坛里有没有熟悉美国法律的大牛牵个头,大家抱团集体起诉聚美,费用按持股份额共摊,聚美到现在为止未披露今年任何的报表信息,一定是有原因的,街电诉讼这么大的事件未见披露也不正常,论坛里的高人可以帮着找找诉讼理由;第二种就是中国式的做法,大家组群约个时间去聚美的办公地点,要求他们给股东一个说法,不给他们压力,他们根本就不理我们,对不对? 个人建议持股的兄弟姐妹现在不要再抛聚美股票了,三点理由:一、如果聚美是通过回购来实现退市,那么不能让他们以这么便宜的价格得手;二、如果投资者失去信心,但毕竟聚美还有那么多现金,还有宝宝树的股权,街电12口出问题但还有6口的,电视剧收视率也还高的,按照现在的市值计算已经低估,这个价位真是没必要再割肉了;三、如果聚美涉嫌欺诈,那把股票卖了,如何进行维权索赔呢? 抛砖引玉,欢迎大家集思广益,共同商","listText":"$聚美优品(JMEI)$ 当前聚美优品这样的一个股价表现,个人感觉有三点可能的原因:一、陈欧想要退市,之前私有化失败后,他准备用更便宜价格以回购方式进行退市,所以故意打压股价,一方面可以便宜价格回购股票,另一方面逼小股东退出,因为按照纽交所的退市规定,总股东数小于400人就将启动退市程序;二、投资者不看好公司发展前景,特别是现在街电的一审败诉,二审前景不明,投资者恐慌性抛售;三、聚美一直提供虚假报表,现在编不下去了,所以一方面一直不发布报表,另一方面干脆买光流通股退市算了。但不管是哪种情况,聚美对投资者不重视是肯定的,聚美官网上提供的联系电话和邮箱都是外包第三方公司的,电话打过去,一个接电话的男士永远都说聚美的事情由他同事在负责,同事很忙一直在出差,让我有事发邮件,很快会有答复,于是我信了,发了好几次邮件,但都似泥牛入海,音信全无!不信大家可以打电话发邮件试试。(网址:ir.jumei.com) 个人认为现在可以采取两种处理方式,一种是美国式的做法,也就是说,论坛里有没有熟悉美国法律的大牛牵个头,大家抱团集体起诉聚美,费用按持股份额共摊,聚美到现在为止未披露今年任何的报表信息,一定是有原因的,街电诉讼这么大的事件未见披露也不正常,论坛里的高人可以帮着找找诉讼理由;第二种就是中国式的做法,大家组群约个时间去聚美的办公地点,要求他们给股东一个说法,不给他们压力,他们根本就不理我们,对不对? 个人建议持股的兄弟姐妹现在不要再抛聚美股票了,三点理由:一、如果聚美是通过回购来实现退市,那么不能让他们以这么便宜的价格得手;二、如果投资者失去信心,但毕竟聚美还有那么多现金,还有宝宝树的股权,街电12口出问题但还有6口的,电视剧收视率也还高的,按照现在的市值计算已经低估,这个价位真是没必要再割肉了;三、如果聚美涉嫌欺诈,那把股票卖了,如何进行维权索赔呢? 抛砖引玉,欢迎大家集思广益,共同商","text":"$聚美优品(JMEI)$ 当前聚美优品这样的一个股价表现,个人感觉有三点可能的原因:一、陈欧想要退市,之前私有化失败后,他准备用更便宜价格以回购方式进行退市,所以故意打压股价,一方面可以便宜价格回购股票,另一方面逼小股东退出,因为按照纽交所的退市规定,总股东数小于400人就将启动退市程序;二、投资者不看好公司发展前景,特别是现在街电的一审败诉,二审前景不明,投资者恐慌性抛售;三、聚美一直提供虚假报表,现在编不下去了,所以一方面一直不发布报表,另一方面干脆买光流通股退市算了。但不管是哪种情况,聚美对投资者不重视是肯定的,聚美官网上提供的联系电话和邮箱都是外包第三方公司的,电话打过去,一个接电话的男士永远都说聚美的事情由他同事在负责,同事很忙一直在出差,让我有事发邮件,很快会有答复,于是我信了,发了好几次邮件,但都似泥牛入海,音信全无!不信大家可以打电话发邮件试试。(网址:ir.jumei.com) 个人认为现在可以采取两种处理方式,一种是美国式的做法,也就是说,论坛里有没有熟悉美国法律的大牛牵个头,大家抱团集体起诉聚美,费用按持股份额共摊,聚美到现在为止未披露今年任何的报表信息,一定是有原因的,街电诉讼这么大的事件未见披露也不正常,论坛里的高人可以帮着找找诉讼理由;第二种就是中国式的做法,大家组群约个时间去聚美的办公地点,要求他们给股东一个说法,不给他们压力,他们根本就不理我们,对不对? 个人建议持股的兄弟姐妹现在不要再抛聚美股票了,三点理由:一、如果聚美是通过回购来实现退市,那么不能让他们以这么便宜的价格得手;二、如果投资者失去信心,但毕竟聚美还有那么多现金,还有宝宝树的股权,街电12口出问题但还有6口的,电视剧收视率也还高的,按照现在的市值计算已经低估,这个价位真是没必要再割肉了;三、如果聚美涉嫌欺诈,那把股票卖了,如何进行维权索赔呢? 抛砖引玉,欢迎大家集思广益,共同商","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":4,"commentSize":26,"repostSize":0,"link":"https://laohu8.com/post/236524","isVote":1,"tweetType":1,"viewCount":2005,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3495076280029345","authorId":"3495076280029345","name":"华尔街股评","avatar":"https://static.tigerbbs.com/746e7d67739c45b7a0d940eda68e7a48","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3495076280029345","idStr":"3495076280029345"},"content":"发这个贴的人也是脑残一个!**的,股市有风险,投资就是看智慧,你输了就得认输!懂吗","text":"发这个贴的人也是脑残一个!**的,股市有风险,投资就是看智慧,你输了就得认输!懂吗","html":"发这个贴的人也是脑残一个!**的,股市有风险,投资就是看智慧,你输了就得认输!懂吗"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":73408,"gmtCreate":1499734622160,"gmtModify":1704878692032,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"title":"感觉这里像赌场","htmlText":"$特斯拉(TSLA)$ 老虎的论坛里到处都是谈论期权的帖子,好像所有人都在期权里赚了大钱!期权就像赌博,长期来看“十赌九输”,从没听说过哪个投资大师是靠期权博取了超额利润!这个帖子发出肯定会受到一大帮期权“高手们”狠喷,即使这样我还是要提醒一句“远离期权、远离赌场”,如果你看好一支股票,那就买正股吧!有多少钱买多少股,不要加杠杆,祝虎友们投资发大财!","listText":"$特斯拉(TSLA)$ 老虎的论坛里到处都是谈论期权的帖子,好像所有人都在期权里赚了大钱!期权就像赌博,长期来看“十赌九输”,从没听说过哪个投资大师是靠期权博取了超额利润!这个帖子发出肯定会受到一大帮期权“高手们”狠喷,即使这样我还是要提醒一句“远离期权、远离赌场”,如果你看好一支股票,那就买正股吧!有多少钱买多少股,不要加杠杆,祝虎友们投资发大财!","text":"$特斯拉(TSLA)$ 老虎的论坛里到处都是谈论期权的帖子,好像所有人都在期权里赚了大钱!期权就像赌博,长期来看“十赌九输”,从没听说过哪个投资大师是靠期权博取了超额利润!这个帖子发出肯定会受到一大帮期权“高手们”狠喷,即使这样我还是要提醒一句“远离期权、远离赌场”,如果你看好一支股票,那就买正股吧!有多少钱买多少股,不要加杠杆,祝虎友们投资发大财!","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":31,"repostSize":0,"link":"https://laohu8.com/post/73408","isVote":1,"tweetType":1,"viewCount":2255,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3451648860565086","authorId":"3451648860565086","name":"Danazy","avatar":"https://static.laohu8.com/f1e9f5ea43e4478e6a0e64aa387c4f3b","crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3451648860565086","idStr":"3451648860565086"},"content":"哈哈,看到同志了。我也只买正股,坚持只买自己专业领域的公司,只拿长线股。像特斯拉我不了解,所以只是偶尔过来看看而已。","text":"哈哈,看到同志了。我也只买正股,坚持只买自己专业领域的公司,只拿长线股。像特斯拉我不了解,所以只是偶尔过来看看而已。","html":"哈哈,看到同志了。我也只买正股,坚持只买自己专业领域的公司,只拿长线股。像特斯拉我不了解,所以只是偶尔过来看看而已。"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":73408,"gmtCreate":1499734622160,"gmtModify":1704878692032,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"title":"感觉这里像赌场","htmlText":"$特斯拉(TSLA)$ 老虎的论坛里到处都是谈论期权的帖子,好像所有人都在期权里赚了大钱!期权就像赌博,长期来看“十赌九输”,从没听说过哪个投资大师是靠期权博取了超额利润!这个帖子发出肯定会受到一大帮期权“高手们”狠喷,即使这样我还是要提醒一句“远离期权、远离赌场”,如果你看好一支股票,那就买正股吧!有多少钱买多少股,不要加杠杆,祝虎友们投资发大财!","listText":"$特斯拉(TSLA)$ 老虎的论坛里到处都是谈论期权的帖子,好像所有人都在期权里赚了大钱!期权就像赌博,长期来看“十赌九输”,从没听说过哪个投资大师是靠期权博取了超额利润!这个帖子发出肯定会受到一大帮期权“高手们”狠喷,即使这样我还是要提醒一句“远离期权、远离赌场”,如果你看好一支股票,那就买正股吧!有多少钱买多少股,不要加杠杆,祝虎友们投资发大财!","text":"$特斯拉(TSLA)$ 老虎的论坛里到处都是谈论期权的帖子,好像所有人都在期权里赚了大钱!期权就像赌博,长期来看“十赌九输”,从没听说过哪个投资大师是靠期权博取了超额利润!这个帖子发出肯定会受到一大帮期权“高手们”狠喷,即使这样我还是要提醒一句“远离期权、远离赌场”,如果你看好一支股票,那就买正股吧!有多少钱买多少股,不要加杠杆,祝虎友们投资发大财!","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":31,"repostSize":0,"link":"https://laohu8.com/post/73408","isVote":1,"tweetType":1,"viewCount":2255,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3451648860565086","authorId":"3451648860565086","name":"Danazy","avatar":"https://static.laohu8.com/f1e9f5ea43e4478e6a0e64aa387c4f3b","crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3451648860565086","idStr":"3451648860565086"},"content":"哈哈,看到同志了。我也只买正股,坚持只买自己专业领域的公司,只拿长线股。像特斯拉我不了解,所以只是偶尔过来看看而已。","text":"哈哈,看到同志了。我也只买正股,坚持只买自己专业领域的公司,只拿长线股。像特斯拉我不了解,所以只是偶尔过来看看而已。","html":"哈哈,看到同志了。我也只买正股,坚持只买自己专业领域的公司,只拿长线股。像特斯拉我不了解,所以只是偶尔过来看看而已。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":236524,"gmtCreate":1533616203588,"gmtModify":1704769514351,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"title":"集思广益,共同商讨应对之策","htmlText":"$聚美优品(JMEI)$ 当前聚美优品这样的一个股价表现,个人感觉有三点可能的原因:一、陈欧想要退市,之前私有化失败后,他准备用更便宜价格以回购方式进行退市,所以故意打压股价,一方面可以便宜价格回购股票,另一方面逼小股东退出,因为按照纽交所的退市规定,总股东数小于400人就将启动退市程序;二、投资者不看好公司发展前景,特别是现在街电的一审败诉,二审前景不明,投资者恐慌性抛售;三、聚美一直提供虚假报表,现在编不下去了,所以一方面一直不发布报表,另一方面干脆买光流通股退市算了。但不管是哪种情况,聚美对投资者不重视是肯定的,聚美官网上提供的联系电话和邮箱都是外包第三方公司的,电话打过去,一个接电话的男士永远都说聚美的事情由他同事在负责,同事很忙一直在出差,让我有事发邮件,很快会有答复,于是我信了,发了好几次邮件,但都似泥牛入海,音信全无!不信大家可以打电话发邮件试试。(网址:ir.jumei.com) 个人认为现在可以采取两种处理方式,一种是美国式的做法,也就是说,论坛里有没有熟悉美国法律的大牛牵个头,大家抱团集体起诉聚美,费用按持股份额共摊,聚美到现在为止未披露今年任何的报表信息,一定是有原因的,街电诉讼这么大的事件未见披露也不正常,论坛里的高人可以帮着找找诉讼理由;第二种就是中国式的做法,大家组群约个时间去聚美的办公地点,要求他们给股东一个说法,不给他们压力,他们根本就不理我们,对不对? 个人建议持股的兄弟姐妹现在不要再抛聚美股票了,三点理由:一、如果聚美是通过回购来实现退市,那么不能让他们以这么便宜的价格得手;二、如果投资者失去信心,但毕竟聚美还有那么多现金,还有宝宝树的股权,街电12口出问题但还有6口的,电视剧收视率也还高的,按照现在的市值计算已经低估,这个价位真是没必要再割肉了;三、如果聚美涉嫌欺诈,那把股票卖了,如何进行维权索赔呢? 抛砖引玉,欢迎大家集思广益,共同商","listText":"$聚美优品(JMEI)$ 当前聚美优品这样的一个股价表现,个人感觉有三点可能的原因:一、陈欧想要退市,之前私有化失败后,他准备用更便宜价格以回购方式进行退市,所以故意打压股价,一方面可以便宜价格回购股票,另一方面逼小股东退出,因为按照纽交所的退市规定,总股东数小于400人就将启动退市程序;二、投资者不看好公司发展前景,特别是现在街电的一审败诉,二审前景不明,投资者恐慌性抛售;三、聚美一直提供虚假报表,现在编不下去了,所以一方面一直不发布报表,另一方面干脆买光流通股退市算了。但不管是哪种情况,聚美对投资者不重视是肯定的,聚美官网上提供的联系电话和邮箱都是外包第三方公司的,电话打过去,一个接电话的男士永远都说聚美的事情由他同事在负责,同事很忙一直在出差,让我有事发邮件,很快会有答复,于是我信了,发了好几次邮件,但都似泥牛入海,音信全无!不信大家可以打电话发邮件试试。(网址:ir.jumei.com) 个人认为现在可以采取两种处理方式,一种是美国式的做法,也就是说,论坛里有没有熟悉美国法律的大牛牵个头,大家抱团集体起诉聚美,费用按持股份额共摊,聚美到现在为止未披露今年任何的报表信息,一定是有原因的,街电诉讼这么大的事件未见披露也不正常,论坛里的高人可以帮着找找诉讼理由;第二种就是中国式的做法,大家组群约个时间去聚美的办公地点,要求他们给股东一个说法,不给他们压力,他们根本就不理我们,对不对? 个人建议持股的兄弟姐妹现在不要再抛聚美股票了,三点理由:一、如果聚美是通过回购来实现退市,那么不能让他们以这么便宜的价格得手;二、如果投资者失去信心,但毕竟聚美还有那么多现金,还有宝宝树的股权,街电12口出问题但还有6口的,电视剧收视率也还高的,按照现在的市值计算已经低估,这个价位真是没必要再割肉了;三、如果聚美涉嫌欺诈,那把股票卖了,如何进行维权索赔呢? 抛砖引玉,欢迎大家集思广益,共同商","text":"$聚美优品(JMEI)$ 当前聚美优品这样的一个股价表现,个人感觉有三点可能的原因:一、陈欧想要退市,之前私有化失败后,他准备用更便宜价格以回购方式进行退市,所以故意打压股价,一方面可以便宜价格回购股票,另一方面逼小股东退出,因为按照纽交所的退市规定,总股东数小于400人就将启动退市程序;二、投资者不看好公司发展前景,特别是现在街电的一审败诉,二审前景不明,投资者恐慌性抛售;三、聚美一直提供虚假报表,现在编不下去了,所以一方面一直不发布报表,另一方面干脆买光流通股退市算了。但不管是哪种情况,聚美对投资者不重视是肯定的,聚美官网上提供的联系电话和邮箱都是外包第三方公司的,电话打过去,一个接电话的男士永远都说聚美的事情由他同事在负责,同事很忙一直在出差,让我有事发邮件,很快会有答复,于是我信了,发了好几次邮件,但都似泥牛入海,音信全无!不信大家可以打电话发邮件试试。(网址:ir.jumei.com) 个人认为现在可以采取两种处理方式,一种是美国式的做法,也就是说,论坛里有没有熟悉美国法律的大牛牵个头,大家抱团集体起诉聚美,费用按持股份额共摊,聚美到现在为止未披露今年任何的报表信息,一定是有原因的,街电诉讼这么大的事件未见披露也不正常,论坛里的高人可以帮着找找诉讼理由;第二种就是中国式的做法,大家组群约个时间去聚美的办公地点,要求他们给股东一个说法,不给他们压力,他们根本就不理我们,对不对? 个人建议持股的兄弟姐妹现在不要再抛聚美股票了,三点理由:一、如果聚美是通过回购来实现退市,那么不能让他们以这么便宜的价格得手;二、如果投资者失去信心,但毕竟聚美还有那么多现金,还有宝宝树的股权,街电12口出问题但还有6口的,电视剧收视率也还高的,按照现在的市值计算已经低估,这个价位真是没必要再割肉了;三、如果聚美涉嫌欺诈,那把股票卖了,如何进行维权索赔呢? 抛砖引玉,欢迎大家集思广益,共同商","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":4,"commentSize":26,"repostSize":0,"link":"https://laohu8.com/post/236524","isVote":1,"tweetType":1,"viewCount":2005,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3495076280029345","authorId":"3495076280029345","name":"华尔街股评","avatar":"https://static.tigerbbs.com/746e7d67739c45b7a0d940eda68e7a48","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3495076280029345","idStr":"3495076280029345"},"content":"发这个贴的人也是脑残一个!**的,股市有风险,投资就是看智慧,你输了就得认输!懂吗","text":"发这个贴的人也是脑残一个!**的,股市有风险,投资就是看智慧,你输了就得认输!懂吗","html":"发这个贴的人也是脑残一个!**的,股市有风险,投资就是看智慧,你输了就得认输!懂吗"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":800346229,"gmtCreate":1627281894961,"gmtModify":1627281894961,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"的确,感觉像是在写童话故事[微笑] ","listText":"的确,感觉像是在写童话故事[微笑] ","text":"的确,感觉像是在写童话故事[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800346229","repostId":"1199944196","repostType":4,"isVote":1,"tweetType":1,"viewCount":1549,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":997236574,"gmtCreate":1567554851998,"gmtModify":1704716321964,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JMEI\">$聚美优品(JMEI)$</a>什么时候能够出半年报,已经9月了","listText":"<a href=\"https://laohu8.com/S/JMEI\">$聚美优品(JMEI)$</a>什么时候能够出半年报,已经9月了","text":"$聚美优品(JMEI)$什么时候能够出半年报,已经9月了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/997236574","isVote":1,"tweetType":1,"viewCount":3061,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3496719751318586","authorId":"3496719751318586","name":"Alexliu169","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3496719751318586","idStr":"3496719751318586"},"content":"说是9月9","text":"说是9月9","html":"说是9月9"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":919866147,"gmtCreate":1576623790989,"gmtModify":1704272095795,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JMEI\">$聚美优品(JMEI)$</a>请问各位大佬,聚美半年报有发过吗?都快年底了,谢谢!","listText":"<a href=\"https://laohu8.com/S/JMEI\">$聚美优品(JMEI)$</a>请问各位大佬,聚美半年报有发过吗?都快年底了,谢谢!","text":"$聚美优品(JMEI)$请问各位大佬,聚美半年报有发过吗?都快年底了,谢谢!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/919866147","isVote":1,"tweetType":1,"viewCount":2569,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":362423387,"gmtCreate":1614659610749,"gmtModify":1703479490834,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"这篇文章不错,转发给大家看看","listText":"这篇文章不错,转发给大家看看","text":"这篇文章不错,转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/362423387","repostId":"2114034843","repostType":4,"isVote":1,"tweetType":1,"viewCount":1755,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":388981548,"gmtCreate":1613010595284,"gmtModify":1703768337392,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"这篇文章不错,转发给大家看看","listText":"这篇文章不错,转发给大家看看","text":"这篇文章不错,转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/388981548","repostId":"2103135838","repostType":2,"repost":{"id":"2103135838","pubTimestamp":1610626380,"share":"https://www.laohu8.com/m/news/2103135838?lang=&edition=full","pubTime":"2021-01-14 20:13","market":"us","language":"en","title":"Aphria Inc. Announces Record Second Quarter Fiscal Year 2021 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2103135838","media":"PR Newswire","summary":"Reports Net Revenue of $160.5 Million, an Increase of 33% from Prior Year Quarter Adjusted EBITDA of","content":"<div>\n<p>Reports Net Revenue of $160.5 Million, an Increase of 33% from Prior Year Quarter Adjusted EBITDA of $12.6 Million Marks Seventh Consecutive Quarter of Increasing Positive Adjusted EBITDACash Cost Per...</p>\n\n<a href=\"https://finance.yahoo.com/news/aphria-inc-announces-record-second-121300973.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aphria Inc. Announces Record Second Quarter Fiscal Year 2021 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAphria Inc. Announces Record Second Quarter Fiscal Year 2021 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-01-14 20:13 GMT+8 <a href=https://finance.yahoo.com/news/aphria-inc-announces-record-second-121300973.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports Net Revenue of $160.5 Million, an Increase of 33% from Prior Year Quarter Adjusted EBITDA of $12.6 Million Marks Seventh Consecutive Quarter of Increasing Positive Adjusted EBITDACash Cost Per...</p>\n\n<a href=\"https://finance.yahoo.com/news/aphria-inc-announces-record-second-121300973.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/loACoTH9px4Zk16iMByMHQ--~B/aD0xNjI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/xiCU8M84wCzhcVNRudtylQ--~B/aD0xNjI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/d3051d7d444063e3e4edb6abf0e97a39","relate_stocks":{"APHA":"Aphria Inc."},"source_url":"https://finance.yahoo.com/news/aphria-inc-announces-record-second-121300973.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2103135838","content_text":"Reports Net Revenue of $160.5 Million, an Increase of 33% from Prior Year Quarter Adjusted EBITDA of $12.6 Million Marks Seventh Consecutive Quarter of Increasing Positive Adjusted EBITDACash Cost Per Gram Decreases for the Fifth Consecutive Quarter to $0.79Completed Accretive, Strategic Acquisition of SweetWater\nLEAMINGTON, ON, Jan. 14, 2021 /PRNewswire/ - Aphria Inc. (\"Aphria,\" \"we,\" or the \"Company\") (TSX: APHA) (Nasdaq: APHA), a leading global cannabis-lifestyle consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today reported its financial results for the second quarter and six months ended November 30, 2020. All amounts are expressed in Canadian dollars, unless otherwise noted and except for per gram, kilogram, kilogram equivalents, and per share amounts. \n\n \n\n\"We are pleased with our second quarter results which reflect the strength of our diversified global cannabis and consumer packaged goods businesses,\" said Irwin D. Simon, Chairman and Chief Executive Officer. \"Our market leading adult-use cannabis brands and sales remained strong and our international medical cannabis sales are off to a solid start. We also advanced our long-term vision for building a global cannabis life-style consumer packaged foods company positioned for sustainable, profitable growth with the completion of our acquisition of SweetWater late in the second quarter. In addition to advancing our long-term vision and growth objectives, the addition of SweetWater is a cornerstone within our U.S. strategy and a strong complement to our existing Aphria business that we believe will return compelling financial benefits. We already hit the ground running by starting to build upon the strengths of each of our respective complementary cannabis lifestyle brands broadening our consumer reach and enhancing loyalty with existing consumers.\"\nSimon continued, \"We remain excited about our recently announced definitive agreement with Tilray to combine to create the largest global cannabis company and are on-track to close the transaction in the second quarter of calendar year 2021. At Aphria, we continue to build on our strong foundation in Canada and internationally to capitalize on growth opportunities utilizing our best-in-class cultivation and manufacturing across a greater distribution footprint and enabling us to connect with an increasing number of consumers and patients with our industry-leading brands and diversified product offerings. Looking forward, we are planning to execute on the significant strategic and financial opportunities provided by the addition of SweetWater and, upon the closing of the Tilray business combination, including our over $100 million anticipated pre-tax synergies, to generate significant value for our stakeholders.\"\nKey Operating Highlights – Second Quarter Fiscal 2021\n\nRecord gross revenue for adult-use cannabis of $72.1 million in the second quarter, an increase of 149% from prior year quarter, representing the seventh consecutive quarter of growth. \nNet cannabis revenue of $67.9 million in the second quarter, an increase of 99% from prior year quarter and an increase of 7% from prior quarter. \nNet revenue of $160.5 million in the second quarter, an increase of 33% from prior year quarter and an increase of 10% from prior quarter. \nCash cost to produce dried cannabis per gram1 of $0.79 in the second quarter, a decrease of 9% from the prior quarter, which represents the fifth consecutive quarter of decreasing cost. \nRecorded seventh consecutive quarter with positive adjusted EBITDA1 and positive adjusted EBITDA from cannabis business1. \nAdjusted EBITDA from cannabis business1 of $12.9 million in the second quarter, an increase of 24% from the prior quarter. \nAdjusted EBITDA1 of $12.6 million in the second quarter, an increase of 26% from the prior quarter. \nEnded second quarter with a strong balance sheet and liquidity, including $320.0 million of proforma cash1 to fund planned Canadian and international growth. \nFree cash flow1 improved $70 million during the second quarter predominantly as a result of increased cash provided by operating activities, as the Company better managed its working capital. \nCompleted first EU-GMP shipment of dried cannabis and cannabis oil to Germany. \nReceived import permit for first EU-GMP shipment of cannabis oil for sale and distribution in Malta. \nCompleted first shipment of medical cannabis to Canndoc for distribution in Israel. \nExecuted supply agreement with ODI Pharma AB, expanding Aphria's international presence into Poland. \nCompleted the accretive, strategic acquisition of SW Brewing Company, LLC, further diversifying the Aphria's product offering, broadening its consumer reach, and enhancing loyalty with consumers. \nExpanded 510 vape offerings across Aphria's award-winning adult-use brand portfolio.\n\nSubsequent Events\n\nReached a definitive agreement to combine with Tilray, Inc. to create the world's largest global cannabis company based on proforma revenue. \nClosed a USD $120 million financing with BMO, providing a USD $20 million revolving facility and a USD $100 million term debt facility. \nBroken Coast expanded its premium cannabis offering with the introduction of a newly developed strain \"Pipe Dream.\" \nReceived a total of six awards, the most awards given to one licensed producer, including four adult-use brands being recognized by the 2020 kind Awards.\n\nKey Financial Highlights (In thousands of Canadian dollars)\n\n\n\n\n\nThree months ended \nThree months ended \n\n\n\nNovember 30, 2020 \nNovember 30, 2019 \n\n\nNet revenue \n$160,532 \n$120,600 \n\n\nGross profit \n$39,492 \n$39,589 \n\n\nAdjusted cannabis gross profit 1 \n$31,167 \n$19,079 \n\n\nAdjusted cannabis gross margin 1 \n45.9% \n56.6% \n\n\nAdjusted beverage alcohol gross profit 1 \n$533 \nN/A \n\n\nAdjusted beverage alcohol gross margin 1 \n60.5% \nN/A \n\n\nAdjusted distribution gross profit 1 \n$12,053 \n$10,959 \n\n\nAdjusted distribution gross margin 1 \n13.1% \n12.7% \n\n\nNet income (loss) \n($120,598) \n($7,929) \n\n\nAdjusted net income (loss) 1 \n$3,219 \n($48,753) \n\n\nAdjusted EBITDA 1 \n$12,572 \n$1,903 \n\n\n\n\n\n\n\n\nQ2-2021 \nQ1-2021 \n\n\nDistribution revenue \n$91,740 \n$82,198 \n\n\nNet cannabis revenue \n$67,911 \n$63,491 \n\n\nNet beverage alcohol revenue \n$881 \n$0 \n\n\nNet revenue \n$160,532 \n$145,689 \n\n\nKilograms (or kilogram equivalents) sold 1 \n26,730 \n20,882 \n\n\nCash cost to produce dried cannabis / gram1 \n$0.79 \n$0.87 \n\n\n\"All-in\" cost of goods sold / gram1 \n$1.30 \n$1.41 \n\n\nAdjusted EBITDA from cannabis business 1 \n$12,887 \n$10,399 \n\n\nAdjusted EBITDA from businesses under development 1 \n($3,199) \n($2,820) \n\n\nAdjusted EBITDA from beverage alcohol business 1 \n$299 \n$0 \n\n\nAdjusted EBITDA from distribution business 1 \n$2,585 \n$2,427 \n\n\nCash and cash equivalents & marketable securities \n$187,997 \n$400,019 \n\n\nProforma cash 1 \n$319,997 \n$400,019 \n\n\nWorking capital \n$399,161 \n$725,512 \n\n\nCapital and intangible asset expenditures - wholly-owned subsidiaries 1 \n$16,935 \n$15,808 \n\n\nCapital and intangible asset expenditures -majority-owned subsidiaries1 \n$2,791 \n$1,496 \n\n\n\n\n\n\n\n\n Source: Aphria Inc. November 30, 2020 MD&A11 \n\n\n\n\n\n\n\n\n___________________________ \n\n\n1 In this press release, reference is made to proforma cash, adjusted cannabis gross profit, adjusted cannabis gross margin, adjusted beverage alcohol gross profit, adjusted beverage alcohol gross margin, adjusted distribution gross profit, adjusted distribution gross margin, adjusted net income (loss), adjusted EBITDA, adjusted EBITDA from cannabis business, adjusted EBITDA from distribution business, adjusted EBITDA from businesses under development, adjusted EBITDA from beverage alcohol business, free cash flow, gram equivalents, cash costs to produce dried cannabis per gram, \"all-in\" cost of sales of dried cannabis per gram, capital and intangible asset expenditures – wholly-owned subsidiaries, and capital and intangible asset expenditures – majority-owned subsidiaries which are not measures of financial performance under International Financial Reporting Standards (IFRS). These metrics and measures are not recognized measures under IFRS, do not have meanings prescribed under IFRS and as a result are unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complementary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of review of our financial information reported under IFRS. Definitions and reconciliations for all terms above can be found in the Company's Management's Discussion and Analysis for the three months ended November 30, 2020, filed on SEDAR and EDGAR. \n\n\n\n\nNet revenue for the three months ended November 30, 2020 was $160.5 million, an increase of 33% from $120.6 million in the same period last year. Second quarter fiscal year 2021 net revenue increased 10% when compared to the prior quarter net revenue of $145.7 million, as a result of an increase in distribution revenue at CC Pharma in Germany and an increase in net cannabis revenue as well as five days of contribution from net beverage alcohol revenue from the acquisition of SweetWater. The increase in distribution revenue is a result of a return to normalized levels from the prior quarter. \nThe average retail selling price of medical cannabis, before excise tax, decreased to $6.96 per gram in the quarter, compared to $7.38 in the prior quarter. The decline is a result of specific pricing programs offered to assist patients in need who have been negatively impacted by the COVID-19 pandemic, along with other promotional programs.\nThe average selling price of adult-use cannabis, before excise tax, increased to $4.29 per gram in the quarter, compared to $4.15 per gram in the prior quarter, primarily related to sales mix.\nAdjusted cannabis gross profit1 for the second quarter was $31.2 million, with an adjusted cannabis gross margin1 of 45.9%, compared to $31.5 million and 49.7% in the prior quarter. The decrease in adjusted cannabis gross profit1 and adjusted cannabis gross margin1 was primarily due to supply and demand and inventory that was liquidated below cost. During the quarter, the Company liquidated older inventory below cost resulting in a gross loss of approximately $1.5 million and the Company incurred under-absorbed overhead of approximately $1.0 million as a result of the Company's planned reduction in operating capacity.\nAdjusted distribution gross profit1 for the second quarter was $12.0 million, with an adjusted distribution gross margin1 of 13.1%, compared to $11.8 million and 14.4% in the prior quarter. The increase in adjusted distribution gross profit1 was a result of an increase in distribution revenue at CC Pharma in Germany. The decrease in the gross margin was a function of product sales mix at CC Pharma in the quarter. \nOperating expenses in the quarter increased to $82.7 million from $54.5 million in the prior quarter and increased from $49.2 million in the prior year. The increase from the prior quarter was primarily due to transaction costs of $22.6 million associated with the acquisition of SweetWater during the quarter and increased share-based compensation largely driven by the increase in the Company's share price. The increase from the prior year was largely consistent with the changes from the prior quarter.\nNet loss for the second quarter of fiscal year 2021 was $120.6 million, or a loss of $0.42 per share, compared to net loss of $5.1 million, or a loss of $0.02 per share in the prior quarter, and a net loss of $7.9 million, or a loss of $0.03 per share for the same period last year. On an adjusted basis excluding the impacts of the items noted in the reconciliation table below, the Company recorded net income for the second quarter of fiscal year 2021 of $3.2 million, or earnings of $0.01 per share.\nAdjusted EBITDA1 increased $2.6 million to $12.6 million for the second quarter compared to $10.0 million in the prior quarter. Adjusted EBITDA from cannabis business1 for the second quarter was $12.9 million compared to $10.4 million in the prior quarter. The adjusted EBITDA loss from businesses under development1 for the second quarter was $3.2 million compared to a loss of $2.8 million in the prior quarter. Adjusted EBITDA from the beverage alcohol business1 was $0.3 million based on a five-day contribution in the second quarter of fiscal 2021. Adjusted EBITDA from distribution business1 for the second quarter was $2.6 million, compared to $2.4 million in the prior quarter.\n\n\n\n\n___________________ \n\n\n2 Adjusted loss per share calculated based on the weighted average number of common shares – basic as disclosed in the Company's financial statements. \n\n\n\n\n\n\n\n\n\nFor the three monthsended November 30, \nFor the six months endedNovember 30, \n\n\n2020 \n2019 \n2020 \n2019 \n\n\n\nNet income (loss) \n$ (120,598) \n$ (7,929) \n$ (125,693) \n$ 8,512 \n\n\n\nUnrealized loss (gain) on convertible debentures \n87,646 \n(49,078) \n87,225 \n(63,285) \n\n\n\nShare-based compensation \n13,595 \n7,563 \n17,856 \n12,519 \n\n\n\nTransaction costs \n22,576 \n691 \n25,624 \n1,426 \n\n\n\nAdjusted net income (loss) \n$ 3,219 \n$ (48,753) \n$ 5,012 \n$ (40,828) \n\n\n\n\n\n\n\n\n\n\n\nAdjusted income (loss) per share - basic2 \n$ 0.01 \n$ (0.19) \n$ 0.02 \n$ (0.16) \n\n\n\n\nThe Company ended the second quarter with a strong balance sheet, including $320.0 million of proforma cash1. Further, the Company's efforts to improve its free cash flow1 were successful in the quarter, as the Company moved closer to its target of generating positive free cash flow1. During the quarter, the Company improved its free cash flow1 by more than $70 million.\n\n\n\n\n\n\n\n\n\n Q2 - 2021 \n Q1 - 2021 \n\n\n\n\n\n\n\n\n\n\n\nCash provided by (used in) operating activities: \n\n\n$ 3,404 \n$ (69,337) \n\n\nInvestment in capital and intangible assets \n\n\n(19,726) \n(17,304) \n\n\nFree cash flow \n\n\n$ (16,322) \n$ (86,641) \n\n\n\n\nConference Call Aphria will host a conference call to discuss these results today at 9:00 am Eastern Time. To listen to the live call, dial (888) 231-8191 from Canada and the U.S. or (647) 427-7450 from International locations and use the passcode 8084651. A telephone replay will be available approximately two hours after the call concludes through February 14, 2021. To access the recording dial (855) 859-2056 and use the passcode 8084651.\nThere will also be a simultaneous, live webcast available on the Investors section of Aphria's website at aphriainc.com. The webcast will be archived for 30 days.\nAphria-Tilray Transaction UpdateAphria and Tilray are committed to keeping shareholders of both companies up to date with developments and significant milestones. \nIf you have questions or need more information about the proposed transaction, please contact Aphria's shareholder communications advisor and proxy solicitation agent, Laurel Hill Advisory Group, by telephone at (877) 452.7184 toll-free in Canada, (416) 304.0211 for international calls or by e-mail at assistance@laurelhill.com.\nWe Have A Good Thing Growing\nAbout Aphria Inc.Aphria Inc. is a leading global cannabis-lifestyle consumer packaged goods company with operations in Canada, United States, Europe and Latin America, that is changing people's lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body and soul and invoke a sense of wellbeing. Aphria's mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. Headquartered in Leamington, Ontario, Aphria cultivates, processes, markets and sells medical and adult-use cannabis, cannabis-derived extracts and derivative cannabis products in Canada under the provisions of the Cannabis Act and globally pursuant to applicable international regulations. Aphria also manufactures, markets and sells alcoholic beverages in the United States. \nFor more information, visit: aphriainc.com\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking information or forward-looking statements (together, \"forward-looking statements\") under applicable securities laws and are expressly qualified by this cautionary statement. Any information or statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements, including, but not limited to, statements in this news release with regards to available cash resources, Canadian and international growth, Aphria's market position, ability to generate consistent growth, net revenue and adjusted EBITDA, benefits of the acquisition of SweetWater, completion of the combination with Tilray and expected synergies from the combination. The Company uses words such as \"forecast\", \"future\", \"should\", \"could\", \"enable\", \"potential\", \"contemplate\", \"believe\", \"anticipate\", \"estimate\", \"plan\", \"expect\", \"intend\", \"may\", \"project\", \"will\", \"would\" and the negative of these terms or similar expressions to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Various assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this news release. Forward-looking statements reflect management's current beliefs with respect to future events and are based on information currently available to management including based on reasonable assumptions, estimates, internal and external analysis and opinions of management considering its experience, perception of trends, current conditions and expected developments as well as other factors that management believes to be relevant as at the date such statements are made. Forward-looking statements involve significant known and unknown risks and uncertainties. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements. Factors that may cause such differences include, but are not limited to, risks associated with [assumptions and expectations described in the Company's critical accounting policies and estimates; assumptions and expectations described in the Company's critical accounting policies and estimates; the adoption and impact of certain accounting pronouncements; the Company's future financial and operating performance; the competitive and business strategies of the Company; the intention to grow the business, operations and potential activities of the Company; the Company's ability to provide a return on investment; the Company's ability to maintain a strong financial position and manage costs; the Company's ability to maximize the utilization of its existing assets and investments; the Company's ability to take a leadership position in the industry; the expected inventory and production capacity of the Company; the expected category growth of the Company's products; the anticipated increase in demand for bulk and saleable flower, and the related growth in the wholesale market; the expected variability of wholesale cannabis revenue; the market for the Company's current and proposed products, including vape pens, as well as the Company's ability to capture market share; the anticipated timing for the release of expected product offerings; the expected cost to produce a gram of dried cannabis; the expected cost to process cannabis oil; the development of affiliated brands, product diversification and future corporate development; expectations with respect to the Company's product development, product offering and the sales mix thereof; the Company's satisfaction of international demand for its products; the Company's plans with respect to importation/exportation; the Company's ability to meet the demand for medical cannabis; the Company's plans to establish strategic partnerships, including collaborations with academic institutions in Germany; whether the Company will have sufficient working capital and its ability to obtain financing required in order to develop its business and continue operations; the Company's expected ongoing contractual relationships, and the terms thereof; the Company's ability to comply with its financial covenants in the future; the applicable laws, regulations, licensing and any amendments thereof related to the cultivation, production and sale of cannabis product in the Canadian and international markets; the grant, renewal and impact of any licence or supplemental licence to conduct activities with cannabis or any amendments thereof; the Company's purpose, mission, vision and values; expectations with respect to crop rotation and harvest, the anticipated future gross margins of the Company and the potential for significant growths or losses; the potential for the Company to record future impairment losses; the performance of the Company's business and operations; the Company's ability to capitalize on the US market; future expenditures, strategic investments and capital activities; the anticipated timing for the first harvest from the Company's German cultivation facility and the expected capacity of such facility; current and future legal actions, and the Company's ability to cover any costs or judgements arising from these actions either through insurance or otherwise; Aphria's and Tilray's strategic business combination and the expected terms, timing and closing of the Arrangement including, receipt of required regulatory approvals, shareholder approvals, court approvals and satisfaction of other closing customary conditions; the expected financial and strategic benefits of the Arrangement; estimates of pro–forma financial information of the Combined Company, including in respect of expected revenues and production of cannabis; expected synergies, including pre–tax synergies, savings and efficiencies from the business combination, including statements in respect of operational efficiencies expected to be generated as a result of the Arrangement in the amount of more than C$100 million of pre–tax annual cost synergies; expectations regarding the Combined Company's business strategies, including in the U.S., and ability to pursue growth opportunities; the expectation that the Combined Company will unlock significant shareholder value; and the expected financial and strategic benefits of the SweetWater acquisition to the Company and its shareholders. The impact of COVID-19 nationally and globally which could have a material adverse impact on Aphria's business, operations and financial results, including disruptions in cultivation and processing, supply chains and sales channels, as well as a deterioration of general economic conditions including national and/or global recessions and the response of governments to the COVID-19 pandemic in respect of the operation of retail stores; general economic conditions; adverse industry events and future steps to be taken in response to COVID-19; and the impacts of Brexit on the Company's German business. Readers are cautioned that the foregoing list is not exhaustive and should consider the other factors discussed under the heading \"Risk Factors\" in Aphria's most recent Annual Information Form and under the heading \"Industry Trends and Risks\" in Aphria's Management's Discussion and Analysis for the three months ended November 30, 2020, each available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.\nThe forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.\nThe schedule below is an excerpt of Aphria Inc.'s financial statements prepared on a basis consistent with IFRS for the three months ended on November 30, 2020 and filed on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. This schedule does not contain all of the information in Aphria Inc.'s financial statements that is important to you. You should read the financial statements and Management's Discussion and Analysis for the three months ended November 30, 2020 carefully to obtain a comprehensive understanding of Aphria Inc.'s financial statements and notes thereto under IFRS and related information.\n\n\n\n\nAphria Inc.Condensed Interim Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) \n\n\n(Unaudited - in thousands of Canadian dollars, except share and per share amounts) \n\n\n\n\n\n\n\n\n\n\n\n\n\nFor the three months endedNovember 30, \nFor the six months ended November 30, \n\n\n\n\n\n\n2020 \n2019 \n2020 \n2019 \n\n\n\n\n\n\n\n\n\nNet revenue \n160,532 \n120,600 \n306,221 \n246,712 \n\n\nCost of goods sold \n116,779 \n90,112 \n219,136 \n188,670 \n\n\n\n\n\n\n\n\n\nGross profit before fair value adjustments \n43,753 \n30,488 \n87,085 \n58,042 \n\n\n\n\n\n\n\n\n\n\nFair value adjustment on sale of inventory \n30,353 \n12,391 \n57,556 \n19,677 \n\n\n\nFair value adjustment on growth of biological assets \n(26,092) \n(21,492) \n(85,242) \n(46,645) \n\n\n\n\n\n\n\n\n\nGross profit \n39,492 \n39,589 \n114,771 \n85,010 \n\n\nOperating expenses: \n\n\n\n\n\n\n\nGeneral and administrative \n27,791 \n22,076 \n56,144 \n44,381 \n\n\n\nShare-based compensation \n13,595 \n7,563 \n17,856 \n12,519 \n\n\n\nSelling \n7,538 \n5,662 \n14,751 \n7,642 \n\n\n\nAmortization \n5,647 \n5,896 \n11,056 \n10,904 \n\n\n\nMarketing and promotion \n5,273 \n6,592 \n11,380 \n12,426 \n\n\n\nResearch and development \n279 \n672 \n428 \n1,282 \n\n\n\nTransaction costs \n22,576 \n691 \n25,624 \n1,426 \n\n\n\n82,699 \n49,152 \n137,239 \n90,580 \n\n\n\n\n\n\n\n\n\nOperating loss \n(43,207) \n(9,563) \n(22,468) \n(5,570) \n\n\n\n\n\n\n\n\n\n\nFinance income (expense), net \n(6,074) \n(5,006) \n(13,277) \n(10,263) \n\n\n\nNon-operating income (expense), net \n(89,796) \n4,568 \n(107,119) \n24,871 \n\n\n\n\n\n\n\n\n\n(Loss) income before income taxes \n(139,077) \n(10,001) \n(142,864) \n9,038 \n\n\n\n\n\n\n\n\n\nIncome taxes (recovery) \n(18,479) \n(2,072) \n(17,171) \n526 \n\n\nNet (loss) income \n(120,598) \n(7,929) \n(125,693) \n8,512 \n\n\n\n\n\n\n\n\n\nOther comprehensive (loss) income \n\n\n\n\n\n\n\nOther comprehensive (loss) income \n(1,418) \n(310) \n1,058 \n(1,996) \n\n\nComprehensive (loss) income \n$(122,016) \n$(8,239) \n$(124,635) \n$6,516 \n\n\n\n\n\n\n\n\n\nTotal comprehensive income (loss) attributable to: \n\n\n\n\n\n\n\nShareholders of Aphria Inc. \n(135,224) \n(7,876) \n(153,466) \n7,050 \n\n\n\nNon-controlling interests \n13,208 \n(363) \n28,831 \n(534) \n\n\n\n$(122,016) \n$(8,239) \n$(124,635) \n$6,516 \n\n\n\n\n\n\n\n\n\nWeighted average number of common shares – basic \n290,511,461 \n251,833,217 \n288,995,810 \n251,468,984 \n\n\nWeighted average number of common shares - diluted \n290,511,461 \n251,833,217 \n288,995,810 \n252,427,777 \n\n\n\n\n\n\n\n\n\n(Loss) income per share - basic \n$(0.42) \n$(0.03) \n$(0.43) \n$0.03 \n\n\n(Loss) income per share - diluted \n$(0.42) \n$(0.03) \n$(0.43) \n$0.03 \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAphria Inc.Condensed Interim Consolidated Statements of Financial Position \n\n\n(Unaudited - in thousands of Canadian dollars) \n\n\n\n\n\n\n\n\n\n\n\n\n\nNovember 30, 2020 \nMay 31, 2020 \n\n\nAssets \n\n\n\n\nCurrent assets \n\n\n\n\n\nCash and cash equivalents \n$187,997 \n$497,222 \n\n\n\nAccounts receivable \n96,177 \n55,796 \n\n\n\nPrepaids and other current assets \n48,162 \n42,983 \n\n\n\nInventory \n321,484 \n264,321 \n\n\n\nBiological assets \n28,952 \n28,341 \n\n\n\nCurrent portion of convertible notes receivable \n9,371 \n14,626 \n\n\n\n692,143 \n903,289 \n\n\n\nCapital assets \n655,114 \n587,163 \n\n\n\nIntangible assets \n686,440 \n363,037 \n\n\n\nPromissory notes receivable \n3,000 \n-- \n\n\n\nLong-term investments \n21,815 \n27,016 \n\n\n\nGoodwill \n752,289 \n617,934 \n\n\n\n$2,810,801 \n$2,498,439 \n\n\nLiabilities \n\n\n\n\nCurrent liabilities \n\n\n\n\n\nBank indebtedness \n$5,111 \n$537 \n\n\n\nAccounts payable and accrued liabilities \n254,318 \n152,750 \n\n\n\nIncome taxes payable \n16,576 \n6,410 \n\n\n\nDeferred revenue \n-- \n902 \n\n\n\nCurrent portion of lease liabilities \n1,767 \n1,315 \n\n\n\nCurrent portion of long-term debt \n15,210 \n8,467 \n\n\n\n292,982 \n170,381 \n\n\nLong-term liabilities \n\n\n\n\n\nLease liabilities \n44,896 \n5,828 \n\n\n\nLong-term debt \n122,533 \n129,637 \n\n\n\nConvertible debentures \n358,008 \n270,783 \n\n\n\nDeferred tax liability \n45,391 \n83,468 \n\n\n\n863,810 \n660,097 \n\n\nShareholders' equity \n\n\n\n\n\nShare capital \n2,078,343 \n1,846,938 \n\n\n\nWarrants \n360 \n360 \n\n\n\nShare-based payment reserve \n29,600 \n27,721 \n\n\n\nAccumulated other comprehensive loss \n(211) \n(1,269) \n\n\n\nDeficit \n(215,739) \n(61,215) \n\n\n\n1,892,353 \n1,812,535 \n\n\n\nNon-controlling interests \n54,638 \n25,807 \n\n\n\n1,946,991 \n1,838,342 \n\n\n\n$2,810,801 \n$2,498,439 \n\n\n\n\nAdjusted EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA as net income (loss), plus (minus) income taxes (recovery), plus (minus) finance (income) expense, net, plus (minus) non-operating (income) loss, net, plus amortization3, plus share-based compensation, plus (minus) non-cash fair value adjustments on sale of inventory and on growth of biological assets, plus impairment, plus transaction costs and certain one-time non-operating expenses, as determined by management, all as follows:\n\n\n\n\n\nFor the three monthsended November 30, \nFor the six months endedNovember 30, \n\n\n2020 \n2019 \n2020 \n2019 \n\n\n\nNet income (loss) \n$ (120,598) \n$ (7,929) \n$ (125,693) \n$ 8,512 \n\n\n\nIncome taxes \n(18,479) \n(2,072) \n(17,171) \n526 \n\n\n\nFinance expense, net \n6,074 \n5,006 \n13,277 \n10,263 \n\n\n\nNon-operating (income) loss, net \n89,796 \n(4,568) \n107,119 \n(24,871) \n\n\n\nAmortization3 \n15,347 \n12,313 \n29,252 \n21,531 \n\n\n\nShare-based compensation \n13,595 \n7,563 \n17,856 \n12,519 \n\n\n\nFair value adjustment on sale of inventory \n30,353 \n12,391 \n57,556 \n19,677 \n\n\n\nFair value adjustment on growth of biological assets \n(26,092) \n(21,492) \n(85,242) \n(46,645) \n\n\n\nTransaction costs \n22,576 \n691 \n25,624 \n1,426 \n\n\n Adjusted EBITDA \n$ 12,572 \n$ 1,903 \n$ 22,578 \n$ 2,938 \n\n\n\n\n\n\n\n\n\n_______________ \n\n\n3 \nAs disclosed on the Condensed Interim Consolidated Statements of Cash Flows \n\n\n\n\n\n\n View original content to download multimedia:http://www.prnewswire.com/news-releases/aphria-inc-announces-record-second-quarter-fiscal-year-2021-results-301208419.html\nSOURCE Aphria Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":317715782,"gmtCreate":1612485478546,"gmtModify":1703762507183,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"这篇文章不错,转发给大家看看","listText":"这篇文章不错,转发给大家看看","text":"这篇文章不错,转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/317715782","repostId":"2108793032","repostType":2,"repost":{"id":"2108793032","pubTimestamp":1612388873,"share":"https://www.laohu8.com/m/news/2108793032?lang=&edition=full","pubTime":"2021-02-04 05:47","market":"us","language":"en","title":"Cannabis Stocks Pop on News of Jazz-GW Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2108793032","media":"Investopedia","summary":"Cannabis Stocks Pop on News of Jazz-GW MergerJazz Pharmaceuticals agreed to acquire GW Pharmaceutica","content":"<h1>Cannabis Stocks Pop on News of Jazz-GW Merger</h1><h2>Jazz Pharmaceuticals agreed to acquire GW Pharmaceuticals for $7.2 billion</h2><ul><li></li><li>FACEBOOK</li><li></li><li>TWITTER</li><li></li><li>LINKEDIN</li></ul><p>By</p><p></p><p>Elana Dure</p><p>Updated Feb 3, 2021</p><p>Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals, maker of the first epilepsy drug derived from marijuana, for $7.2 billion in cash and stock.</p><p>The deal, which combines the two biopharmaceutical companies, signifies Jazz’s bet on the long-term prospects of cannabis-based therapies.</p><p>Jazz will pay $200 in cash and $20 in stock per GW share. The transaction is expected to close in the second quarter.</p><p>Cannabis stocks jumped on the news, with shares in Cassava Sciences, Sundial Growers, and Tilray closing up 59%, 16%, and 12%, respectively, on Wednesday.</p><p><img src=\"http://:0\" referrerpolicy=\"no-referrer\"></p><p>Cannabis investors are also optimistic after three Democratic Senators released a statement supporting the decriminalization of marijuana.</p><p>GW’s drug Epidiolex is used to treat rare forms of epilepsy and had global sales of $510 million within two years of its 2018 launch. The deal will strengthen Jazz’s neuroscience portfolio, said Jazz CEO and Chairman Bruce Cozadd.</p><p>\"We have a shared vision of developing and commercializing innovative medicines that address significant unmet needs in neuroscience and an approach of putting patients first,” GW CEO Justin Gover said. “Together, we will have an opportunity to reach and impact more patients through a broader portfolio of neuroscience-focused therapies than ever before.\"</p><p>Shares in GW closed upy 44.5% on the news Wednesday, while shares in Jazz closed down nearly 4%.</p><h3>Article Sources</h3><p>Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our</p><p>editorial policy.</p><ol><li><p>Jazz Pharmaceuticals. \"Jazz Pharmaceuticals to Acquire <a href=\"https://laohu8.com/S/GWPH\">GW Pharmaceuticals plc</a>, Creating an Innovative, High-Growth, Global Biopharma Leader.\" Accessed Feb. 3, 2021.</p></li><li><p>The Wall Street Journal. \"Jazz Pharmaceuticals to Buy Cannabis-Based Drugmaker GW Pharma for $6.7 Billion.\" Accessed Feb 3, 2021.</p></li></ol><p>Compare Accounts</p><p>Advertiser Disclosure</p><p>×The offers that appear in this table are from partnerships from which Investopedia receives compensation.ProviderNameDescription<img referrerpolicy=\"no-referrer\"></p><ul><li>About Us</li><li>Terms of Use</li><li>Dictionary</li><li>Editorial Policy</li><li>Advertise</li><li>News</li><li>Privacy Policy</li><li>Contact Us</li><li>Careers</li><li>California Privacy Notice</li></ul><ul><li>#</li><li>A</li><li>B</li><li>C</li><li>D</li><li>E</li><li>F</li><li>G</li><li>H</li><li>I</li><li>J</li><li>K</li><li>L</li><li>M</li><li>N</li><li>O</li><li>P</li><li>Q</li><li>R</li><li>S</li><li>T</li><li>U</li><li>V</li><li>W</li><li>X</li><li>Y</li><li>Z</li></ul><p></p><p>Investopedia is part of the Dotdash publishing family.</p><p></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cannabis Stocks Pop on News of Jazz-GW Merger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCannabis Stocks Pop on News of Jazz-GW Merger\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-04 05:47 GMT+8 <a href=https://www.investopedia.com/cannabis-stocks-pop-on-news-of-jazz-gw-merger-5104668?utm_campaign=quote-yahoo&utm_source=yahoo&utm_medium=referral&yptr=yahoo><strong>Investopedia</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cannabis Stocks Pop on News of Jazz-GW MergerJazz Pharmaceuticals agreed to acquire GW Pharmaceuticals for $7.2 billionFACEBOOKTWITTERLINKEDINByElana DureUpdated Feb 3, 2021Jazz Pharmaceuticals has ...</p>\n\n<a href=\"https://www.investopedia.com/cannabis-stocks-pop-on-news-of-jazz-gw-merger-5104668?utm_campaign=quote-yahoo&utm_source=yahoo&utm_medium=referral&yptr=yahoo\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNDL":"SNDL Inc.","TLRY":"Tilray Inc.","SAVA":"Cassava Sciences Inc","JAZZ":"爵士制药","GWPH":"GW Pharmaceuticals plc"},"source_url":"https://www.investopedia.com/cannabis-stocks-pop-on-news-of-jazz-gw-merger-5104668?utm_campaign=quote-yahoo&utm_source=yahoo&utm_medium=referral&yptr=yahoo","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2108793032","content_text":"Cannabis Stocks Pop on News of Jazz-GW MergerJazz Pharmaceuticals agreed to acquire GW Pharmaceuticals for $7.2 billionFACEBOOKTWITTERLINKEDINByElana DureUpdated Feb 3, 2021Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals, maker of the first epilepsy drug derived from marijuana, for $7.2 billion in cash and stock.The deal, which combines the two biopharmaceutical companies, signifies Jazz’s bet on the long-term prospects of cannabis-based therapies.Jazz will pay $200 in cash and $20 in stock per GW share. The transaction is expected to close in the second quarter.Cannabis stocks jumped on the news, with shares in Cassava Sciences, Sundial Growers, and Tilray closing up 59%, 16%, and 12%, respectively, on Wednesday.Cannabis investors are also optimistic after three Democratic Senators released a statement supporting the decriminalization of marijuana.GW’s drug Epidiolex is used to treat rare forms of epilepsy and had global sales of $510 million within two years of its 2018 launch. The deal will strengthen Jazz’s neuroscience portfolio, said Jazz CEO and Chairman Bruce Cozadd.\"We have a shared vision of developing and commercializing innovative medicines that address significant unmet needs in neuroscience and an approach of putting patients first,” GW CEO Justin Gover said. “Together, we will have an opportunity to reach and impact more patients through a broader portfolio of neuroscience-focused therapies than ever before.\"Shares in GW closed upy 44.5% on the news Wednesday, while shares in Jazz closed down nearly 4%.Article SourcesInvestopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in oureditorial policy.Jazz Pharmaceuticals. \"Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader.\" Accessed Feb. 3, 2021.The Wall Street Journal. \"Jazz Pharmaceuticals to Buy Cannabis-Based Drugmaker GW Pharma for $6.7 Billion.\" Accessed Feb 3, 2021.Compare AccountsAdvertiser Disclosure×The offers that appear in this table are from partnerships from which Investopedia receives compensation.ProviderNameDescriptionAbout UsTerms of UseDictionaryEditorial PolicyAdvertiseNewsPrivacy PolicyContact UsCareersCalifornia Privacy Notice#ABCDEFGHIJKLMNOPQRSTUVWXYZInvestopedia is part of the Dotdash publishing family.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":288994,"gmtCreate":1538664190964,"gmtModify":1704776153517,"author":{"id":"3456483327764574","authorId":"3456483327764574","name":"再战","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3456483327764574","idStr":"3456483327764574"},"themes":[],"htmlText":"$奥驰亚(MO)$ 请问各位大咖,分红款何时能够到账啊?","listText":"$奥驰亚(MO)$ 请问各位大咖,分红款何时能够到账啊?","text":"$奥驰亚(MO)$ 请问各位大咖,分红款何时能够到账啊?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/288994","isVote":1,"tweetType":1,"viewCount":3253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}